In this 10th edition of DDI of the Month, host Prof. dr. David Burger welcomes dr. Joe Piscitelli from Pfizer, USA, for an in-depth discussion on the DDI profile of encorafenib.

Encorafenib is a potent and selective small-molecule inhibitor of BRAF V600-mutant kinase, and approved for various malignancies, including non-small cell lung cancer.

Based on in vitro research there was uncertainty about the DDI potential of encorafenib as a precipitant drug. Piscitelli et al. conducted a so-called cocktail study to answer this question.

The study results have recently been published in Clinical Pharmacology & Therapeutics journal: An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer.

Tune in to hear about:

• What is the Inje cocktail and how does it differ from other cocktails?
• What is the effect of encorafenib on various CYP450 enzymes tested in this cocktail study?
• What were the challenges with using caffeine as a CYP1A2 probe?
• Does binimetinib play a role in the DDI profile of its combination with encorafenib?
• Which effects of encorafenib can be expected on drug transporters as they are not included in the Inje cocktail?
• Can encorafenib also be the object of a DDI, or is it only a precipitator?

An insightful episode for clinicians, pharmacists, and researchers involved in managing and studying drug–drug interactions. Don’t miss it—listen now!

Available on: Website | Spotify | Apple Podcasts